

Cynata Investor Presentation

Melbourne, Australia; 14 August 2020: Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has today released a new investor presentation. This will be used to update existing shareholders, potential investors, and other parties.

The presentation highlights the key competitive advantages of Cynata's proprietary Cymerus™ technology, which leverages an induced pluripotent stem cell (iPSC)-derived process to optimise product quality and consistency. Cynata has produced a clinical-grade iPSC bank from a single blood donation and this iPSC bank has the capacity to give rise to an effectively limitless number of mesenchymal stem cell (MSC) doses, thus avoiding inter-donor variability. This enables large quantities of a highly consistent MSC product to be manufactured with minimal MSC culture expansion while maintaining potency. Cynata's Cymerus MSC products have shown encouraging human clinical efficacy results in GvHD, as well as compelling potential in pre-clinical studies for a broad range of indications. Cynata is the most advanced company worldwide in the development of iPSC-derived cell therapy products.

Some of these key advantages have been brought into stark focus by recent FDA commentary on MSC manufacturing processes that require multiple tissue donations from multiple donors.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Claire LaCagnina, U.S. Media Contact, +1 315.765.1462, clacagnina@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus MSCs into Phase 2 trials for GvHD (with licensee Fujifilm), severe complications arising from COVID-19 and critical limb ischemia, and into a Phase 3 clinical trial in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ MSC technology in preclinical models of asthma, diabetic wounds, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.